Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial.

Amongst the current clinical bleeding risk scores, the ORBIT score demonstrated the best discrimination and calibration. All the scores demonstrated, to a variable extent, an interaction with bleeding risk associated with dabigatran or warfarin.